TrialPath

Find a study

Match me to a study

195 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

147 studies on the map

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Valleywise Health Medical Center, PhoenixAn Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis — Clinical Site, DoralStudy of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease — Banner Alzheimer's Institute, PhoenixMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanAmitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease — University of Michigan, Ann ArborA Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — University of Alabama at Birmingham, BirminghamA Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) — Local Institution - 0106, PhoenixLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: — Mayo Clinic in Arizona - Scottsdale, ScottsdaleA Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease — Mirador Therapeutics Selected Site, BirminghamStudy to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease — Local Institution - 0046, HomewoodA Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Banner Alzheimer?s Institute, PhoenixA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) — Chandler Clinical Trials, LLC, ChandlerA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Healthy Brain Clinic, Long BeachA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) — Imaging Endpoints, ScottsdaleStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease — Digestive Health Specialists /ID# 266216, DothanA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) — University of South Alabama (USA) Physicians Group, MobileA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) — Local Institution - 2609, ChandlerStudy of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V — AKDHC Medical Research ServicesLLC, PhoenixA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Sun City Clinical Research, GlendaleEfficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — IMC Gulf Coast Gastroenterology, PC, FairhopeAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — Research Site, PhoenixA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Digestive Health Specialists of the Southeast, DothanA Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis — Site 024, Canoga ParkA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — United Medical Doctors, MurrietaA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, DothanA Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease — Banner Alzheimers Institute, PhoenixA Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease — Investigational Site Number: 8400024, TucsonA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — AZ Gastro Care, ChandlerThe Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study — University of California, San Francisco, San FranciscoHuman Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease. — University of Miami Department of Neurology, MiamiA Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) — Irvine Clinical Research ( Site 1041), IrvinePhase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis — ATP Clinical Research Inc., IrvineA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) — Fullerton Neurology and Headache Center, FullertonScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — University of Alabama at Birmingham, BirminghamMindful Walking Neural Correlates of Executive Function in SC Older Adults at Risk of Dementias — University of South Carolina, ColumbiaA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Gastro Care Institute, LancasterA Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis — AZ Gastro Care - Chandler, ChandlerA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Del Sol Research Management, LLC - Site Number: 8400012, TucsonA Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. — GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400020, Sun CityRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus — University of California Irvine, OrangeA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus — Sl0044 50058, AvondaleA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) — Wallace & Lee Center, Beverly HillsA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus — Research Site, AnnistonPhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). — Pinnacle Research Group Llc, AnnistonA Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis — Investigational Site Number: 8400009, EscondidoStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis — GI Alliance, Sun CityA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease — Cedars Sinai Medical Center, Los AngelesA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) — Digestive Health Specialists ( Site 5064), DothanA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleA Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleA Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). — Banner Alzheimer's Institute, PhoenixA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus — David S Hallegua MD A Professional Corporation, Beverly HillsA Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) — University Of Alabama, BirminghamA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease — UCSD Medical Center, La JollaA Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease — Phoenix Children's Hospital, PhoenixA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease — Phoenix Children's Hospital /ID# 255766, PhoenixA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Cedars Sinai Medical Center, Los AngelesAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Onyx Clinical Research - Site Number: 8400021, PeoriaCrohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease — UCSF Benioff Children's Hospital - Oakland /ID# 262217, OaklandA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado SpringsA Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) — Nkarta Investigational Site, Little RockA Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE — Research Site, San FranciscoVIBRANT: VIB4920 for Active Lupus Nephritis — University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La JollaTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdaleA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — HonorHealth Research and Innovation Institute, ScottsdaleA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants — Loma Linda University health, Loma Linda[18F]PI-2620 Phase 3 Histopathological Study — Barrow Neurological Institute, PhoenixMasupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type — Advanced Research Center, Inc., AnaheimA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis — Clinical Site, PhoenixA Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Sierra Pacific Arthritis and Rheumatology Centers, FresnoA Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis — Phoenix Children's Hospital /ID# 273015, PhoenixA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) — UCSF Medical Center at Mission Bay, San FranciscoAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Onyx Clinical Research - Site Number: 8400021, PeoriaA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, DothanA Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis — One of a Kind Clinical Research Center, ScottsdaleClinical Trial on Agitation in Alzheimer's Dementia — ClinCloud, LLC, MaitlandA Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) — Barrow Neurological Institute, PhoenixSafety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia — Esperanza Clinical, MurrietaStudy of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis — Xencor Investigative Site, ScottsdaleA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis — Arkansas Children's (IP Address), Little RockA Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia — Advanced Research Center, Inc, AnaheimA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Gastro Care Institute, LancasterExtension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) — Connecticut Clinical Research Institute ( Site 0297), BristolOpen-label Extension Study in Participants With Early Alzheimer's Disease — GSK Investigational Site, MaitlandA Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) — Clinnova Research ( Site 1042), AnaheimPrecise Infliximab Exposure and Pharmacodynamic Control — Children's Hospital of Los Angeles, Los AngelesA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus — Investigative Site, Beverly HillsStudy of DISC-0974-201 in Participants With IBD and Anemia — One of a Kind Clinical Research Center, LLC, ScottsdaleA Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease — Irvine Center for Clinical Research /ID# 277752, IrvineA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) — Inland Rheumatology Clinical Trials, Inc., UplandA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Dermatology Research Associates - 300204025, Los AngelesEffects of Stopping Hydroxychloroquine in Elderly Lupus Disease — University of California, Los Angeles, Los AngelesDB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease — Direct Biologics Investigational Site, AuroraA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) — Local Institution - 1227, ChandlerA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants — Emory University, AtlantaA Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) — Gilbert Neurology Partners/CCT Research, GilbertA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease — Clinnova Research, AnaheimClinical Study of SNK01 in Participants With Moderate Alzheimer's Disease — Behavioral Research Specialists, LLC, GlendaleA Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants — US06-0, La PalmaA Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) — The Ohio State University (OSU) Wexner Medical Center, ColumbusPreventing Alzheimer's With Cognitive Training — University of Florida, GainesvilleMoving Beyond Inflammation as a Therapeutic Target for Crohn's Disease — Cedars-Sinai Medical Center, Beverly HillsA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) — Woodholme Gastroenterology Associates, Glen BurnieObe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) — State University of New York Upstate Medical Center (SUNY), SyracuseA Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis — Children's Healthcare of Atlanta, AtlantaA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment — Alloy Clinical Research LLC, KissimmeeSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoIMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy — Hospital for Special Surgery, New YorkLow Dose IL-2 for the Treatment of Crohn's Disease — Boston Children's Hospital, BostonPilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy — Connecticut Children's Medical Center, HartfordFerritin and Iron Burden in SAH sIRB — Univesity of Iowa Hospital and Clinics, Iowa CityDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders — H01- Children's National Hospital, Washington D.C.Standardized Microbiota Transplant Therapy in Crohn's Disease — University of Minnesota, MinneapolisTesting the Pain Clinical Practice Guideline — Future Care Coldspring, BaltimoreEpidemiology and Biomarker Study in Alzheimer's Disease — Care Access - Houston, HoustonPhase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders — MD Anderson Cancer Center, HoustonSenicapoc in Alzheimer's Disease — University of California, Davis Alzheimer's Disease Center, SacramentoStudy of Novel Therapeutics for Acute Remedy of Colitis — Brigham and Women's Hospital, Chestnut HillAutologous Stem Cell Transplantation for Crohn's Disease — UPMC Prebyterian- Adult Gastroenterology, PittsburghHuman Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease. — University of Miami Department of Neurology, MiamiAssessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease — Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, BostonTrial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X) — Johns Hopkins School of Medicine, BaltimoreSafety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease — Weill Cornell Medicine Brain Health Imaging Institute, New YorkCholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition — Vanderbilt University Medical Center Clinical Research Center, NashvilleLongitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease — Columbia University Irving Medical Center, New YorkA Study of AMDX-2011P in Participants With Alzheimer's Disease — Associated Retina Consultants, PhoenixDeep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD) — UCLA TMS Clinical and Research Service, Los AngelesRepurposing Siponimod for Alzheimer's Disease — St. Joseph's Hospital and Medical Center, PhoenixBiomarker-based Trial of NPC-1 for Alzheimer's Pathology — Massachusetts General Hospital, BostonExercise to Improve Brain Health in Older African Americans — Rutgers, The State University of New Jersey - Newark campus, NewarkUAB Alzheimer's Disease Center Core Cohort - Imaging Substudy — University of Alabama at Birmingham Medical Center, BirminghamAlzheimer's Tau Platform: Master Protocol — University of California, San Francisco, San FranciscoSleep Trial to Prevent Alzheimer's Disease — Washington University School of Medicine, St LouisVisualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease — Endeavor Health Systems, EvanstonDORA and LP in Alzheimer's Disease Biomarkers — Washington University in St. Louis, School of Medicine, St LouisOpen-Label Extension Protocol to SNK01-AD01 Study — Behavioral Research Specialists, LLC, GlendaleAssess Fibrin in Brains With AD/ADRD — Massachusetts General Hospital, BostonImpact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) — University of Texas Southwestern Medical Center, DallasBiomarker Exploration in Aging, Cognition and Neurodegeneration — University of California, Irvine, IrvineNicotinic Acid for the Treatment of Alzheimer's Disease — IU Health Neuroscience Center, IndianapolisPET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620 — Perelman Center for Advance Medicine, PhiladelphiaSleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND) — University of Virginia, Charlottesville

Showing the 150 nearest — narrow your filters for fewer, closer studies.